Orion OYJ (OTCMKTS:ORINY) Hits New 52-Week High - Still a Buy?

Key Points

• Orion OYJ reached a new 52-week high of $56.26, up 4.2% during trading, though volume was very light at just 223 shares.
• Jefferies upgraded the stock from “hold” to “strong buy,” giving Orion an overall average rating of “Buy” based on one Strong Buy and one Hold recommendation.
• The company reported quarterly revenue of $623.96 million and EPS of $0.68, alongside strong profitability metrics including a 50.37% return on equity and 28.52% net margin.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $56.26 and last traded at $56.26, with a volume of 223 shares changing hands. The stock had previously closed at $54.7750.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Orion OYJ from a "hold" rating to a "strong-buy" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy".

Orion OYJ Trading Up 4.2%

The business's 50-day moving average price is $47.37 and its two-hundred day moving average price is $41.45. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.64 and a quick ratio of 1.48. The company has a market capitalization of $15.88 billion, a P/E ratio of 23.15 and a beta of 0.07.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter. Orion OYJ had a return on equity of 50.37% and a net margin of 28.52%. The firm had revenue of $623.96 million for the quarter.

About Orion OYJ

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson's disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.